We are live on ! Find out more
FP

Flagship Pioneering Portfolio holdings

AUM $1.16B
1-Year Est. Return 67.93%
This Fund
S&P 500
This Quarter Est. Return
+2.05%
1 Year Est. Return
+67.93%
3 Year Est. Return
-39.17%
5 Year Est. Return
-45.89%
10 Year Est. Return
–
AUM
$1.33B
AUM Growth
-$52.4M
Cap. Flow
-$48.2M
Cap. Flow %
-3.64%
Top 10 Hldgs %
100%
Holding
9
New
–
Increased
1
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$1.03M

Top Sells

Rank Stock Value
1
EVLO
Evelo Biosciences, Inc. Common Stock
EVLO
+$31.1M
2
AXLA
Axcella Health Inc. Common Stock
AXLA
+$12.2M
3
DNLI icon
Denali Therapeutics
DNLI
+$5.94M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNA icon
1
Moderna
MRNA
$21.5B
$961M 72.53%
9,666,038
– –
SANA icon
2
Sana Biotechnology
SANA
$885M
$102M 7.7%
25,001,856
– –
OMGA
3
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$88M 6.64%
29,225,579
– –
FHTX icon
4
Foghorn Therapeutics
FHTX
$285M
$81.7M 6.17%
12,674,120
– –
DNLI icon
5
Denali Therapeutics
DNLI
$3.67B
$49.8M 3.76%
2,319,968
-300,000
-11% -$5.94M
MCRB icon
6
Seres Therapeutics
MCRB
$48.1M
$32.4M 2.45%
1,155,852
– –
SYRS
7
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$10.1M 0.76%
1,293,848
+300,000
+30% +$1.03M
AXLA
8
DELISTED
Axcella Health Inc. Common Stock
AXLA
– –
-1,170,059
Closed -$12.2M
EVLO
9
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
– –
-7,932,624
Closed -$31.1M

Similar funds

AC
AltraVue Capital Bellevue, Washington $1.16B AUM 46.45% 1-Year Est. Return
BI
Bramshill Investments Naples, Florida $1.16B AUM 0.86% 1-Year Est. Return
SCP
Sandhill Capital Partners Buffalo, New York $1.16B AUM 12.37% 1-Year Est. Return
SFG
SNS Financial Group Minneapolis, Minnesota $1.16B AUM 13.88% 1-Year Est. Return
GAB
German American Bancorp Jasper, Indiana $1.16B AUM 25.7% 1-Year Est. Return
AMI
Amica Mutual Insurance Providence, Rhode Island $1.16B AUM 21.34% 1-Year Est. Return
FFP
FourThought Financial Partners Venice, Florida $1.16B AUM 24.95% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Flagship Pioneering's Q4 2023 Portfolio in Review

As of Q4 2023, Flagship Pioneering held 9 positions worth $1.33B, down 3.8% from $1.38B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Flagship Pioneering withdrew a net $48.2M in Q4 2023, closing 2 positions and reducing 1 holding. Its most notable exit was Evelo Biosciences, Inc. Common Stock, an estimated $31.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Flagship Pioneering added an estimated $1.03M to Syros Pharmaceuticals, Inc. Common Stock.

  • Flagship Pioneering added most to Syros Pharmaceuticals, Inc. Common Stock in Q4 2023, an estimated $1.03M increase.
  • Flagship Pioneering's biggest Q4 2023 reduction was Denali Therapeutics, cutting an estimated $5.94M.
  • Flagship Pioneering fully exited Evelo Biosciences, Inc. Common Stock in Q4 2023, selling an estimated $31.1M.
  • Flagship Pioneering's ten largest holdings make up 100% of its $1.33B portfolio in Q4 2023.
  • Flagship Pioneering opened 0 new positions and closed 2 in Q4 2023.
  • Flagship Pioneering's portfolio value fell 3.8% quarter-over-quarter to $1.33B.

Based on Flagship Pioneering's 13F filing for Q4 2023, filed 14 Feb 2024.